Kornimate/medical-research-clean huggingface dataset:
a randomized-control study of gym tonic's community based strength training intervention.

Conditions: Frailty; Muscle Loss; Sarcopenia

Summary: launched in april 2015 , gym tonic is the first of its kind cross-border exercise-as-medicine partnership between research institutions, business enterprises and service providers from singapore and finland. what sets gym tonic apart from other exercise programmes is its singular focus on strength training, necessary for frailty prevention and maintenance of functional independence for the elderly. this randomized-control trial is to validate the gym tonic programme and data as well measuring its effectiveness in improving physical functions and reversing frailty.

the rct is conducted in 3 eldercare community centers. in each center, a group of elderly will be randomly sorted into 2 groups. an intervention group and a control group. the intervention group will go through 12 weeks of gym tonic progressive training programme. while the control group acts as a control. after the first 12 weeks, the intervention group will be going through another 12 weeks of gym tonic maintenance programme, while the control group will be going through the gym tonic progressive training programme. measurements of physical functions, isometric strength and frailty will be conducted pre trial, post 12 weeks and post 24 weeks.

Eligibility criteria:
inclusion criteria: * aged 65 years and above * pre-frail or mildly frail, as measured by the 5 chs criteria of physical frailty: unintentional weight loss, slowness, weakness, exhaustion, low activity level or frail * able to ambulate without personal assistance * enrolled into the 3 sites above exclusion criteria: * bedbound * terminally ill patients with life expectancy \<12 months * significant cognitive impairment * major depression * wear pacemaker * severe audiovisual impairment * any progressive, degenerative neurologic disease * participating in other interventional studies * unavailable to participate for the full duration of the study
pilot breast-dedicated pet camera with 1 millimeter spatial resolution

Conditions: Breast Cancer

Summary: this is a research study of a novel, "breast-dedicated" positron emission tomography (pet) camera with 1 millimeter spatial resolution. the main goal of the study is for the personnel to understand practical and logistical issues with using the camera in the clinic

primary objective to obtain initial experience using the novel, breast-dedicated pet camera design in the breast imaging clinic. secondary objectives to understand, given the 10-fold higher sensitivity of this novel camera, how low we can go with administered tracer dose, and, given the \>100-fold better volumetric spatial resolution, understand the achievable image quality.

Eligibility criteria:
inclusion criteria: * biopsy-confirmed breast cancer measuring ≥ 5 mm on mammogram or ultrasound. * prior diagnostic imaging test(s) with another modality such as mri, ct, or x-ray mammography (or other applicable imaging modalities) within 60 days prior to the study date. * documented written informed consent document. exclusion criteria: * 1. additional condition, or extenuating circumstance that, in the opinion of the investigator, may interfere with study compliance. * known allergies to fdg * pregnant or nursing.
xarelto evidence in real life of patients' preference and satisfaction study

Conditions: Atrial Fibrillation

Summary: the main objective of the study is to assess preferences of non valvular atrial fibrillation (nvaf) patients towards different options of an anticoagulation treatment. patient preferences for anticoagulant treatment attributes (convenience attributes only), based on a discrete choice experiment(dce) interview will be elicited and the impact of switching from vitamin k antagonist(vka) to xarelto® on atrial fibrilation(af) patient treatment satisfaction will be documented, measured by score differences of the anti-clot treatment scale (acts) score in patients switching from vka to rivaroxaban.


Eligibility criteria:
inclusion criteria: * female and male patients ≥ 20 years of age (legal age limit in taiwan) with a confirmed diagnosis of af (non-valvular). * treatment with vka for at least 6 weeks. * decision to initiate treatment with rivaroxaban has been made as per investigator's routine treatment practice. * written informed consent of the patient. * wilingness and capability to conduct two f2f interviews. exclusion criteria: * contraindications to the use of rivaroxaban as outlined in the local product information . * concomitant treatment with any other anticoagulants. * participation in another study (clinical intervention/observational) within the 3 months prior to enrollment. * patients participating in an investigational program with interventions outside of routine clinical practice.
the impact of diaphragm training on dysphagia in bulbar palsy after ischemic stroke

Conditions: Bulbar Palsy

Summary: this was a prospective multicenter study. the patients after stroke with were randomly divided into the observation group and the control group. all patients were given comprehensive rehabilitation therapy. during the treatment, enteral nutrition support was provided for the two groups by intermittent oro-esophageal tube feeding. the observation group will be given diaphragm training nutritional status, dysphagia, quality of life and depression before and after treatment were compared.

dysphagia in patients after stroke continues to be a challenge. this was a prospective multicenter study. the patients after stroke with were randomly divided into the observation group and the control group. all patients were given comprehensive rehabilitation therapy. during the treatment, enteral nutrition support was provided for the two groups by intermittent oro-esophageal tube feeding. the observation group will be given diaphragm training nutritional status, dysphagia, quality of life and depression before and after treatment were compared.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * meeting the diagnostic criteria of bulbar palsy after ischemic stroke; * any degree of dysphagia at admission; * steady vital signs, without severe cognitive impairment or sensory aphasia, able to cooperate with the assessment. * clear mind. exclusion criteria: * complicated with other neurological diseases; * damaged mucosa or incomplete structure in nasopharynx; * tracheostomy tube plugged; * unfeasible to the support of parenteral nutrition; * simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.
virtual reality-supported cardiac rehabilitation: psychological, functional, and physiological perspectives

Conditions: Cardiovascular Diseases; Coronary Arterial Disease (CAD); Myocardial Disease; Heart Disease

Summary: the study aims to evaluate the effectiveness of virtual reality-assisted cardiac rehabilitation compared to conventional cardiac rehabilitation in improving psychological outcomes-depression, stress, anxiety, and kinesiophobia-along with physiological parameters, functional status, physical activity levels, and quality of life in cardiac patients.

this single-blind randomized controlled trial will include 60 participants aged 60 years and older undergoing phase ii cr at the provincial specialist hospital of the blessed virgin mary in częstochowa, poland. participants will be randomly assigned to one of two groups: a conventional cr program or a vr-cr group. both groups will complete a three-week hospital-based cr program involving structured group exercises, interval cycling, and relaxation sessions. the experimental group will additionally receive eight sessions of immersive vr therapy using the vrtierone device, consisting of 20-minute sessions twice weekly. these sessions employ interactive and calming virtual environments to promote relaxation and psychological engagement. outcome measures will be evaluated at baseline (week 0), post-intervention (week 3), and follow-up (week 7). assessments will include patient-reported outcome measures for stress, depression, kinesiophobia, and quality of life, physiological metrics (heart rate, blood pressure, metabolic equivalents), hrv, functional capacity (6mwt), and physical activity levels measured using the pedometers.

Eligibility criteria:
inclusion criteria: * cardiovascular diseases (atherosclerosis, hypertension, coronary artery disease, ischemic heart disease, peripheral artery disease, rheumatic heart disease, deep vein thrombosis, pulmonary embolism, and post-myocardial infraction) * the second stage of cardiac rehabilitation conducted in outpatient settings exclusion criteria: * severe psychiatric disorders (e.g., psychotic symptoms, bipolar disorder) * initiation of psychiatric treatment or individual psychological therapy during the study period * current use of antidepressant medications * cognitive impairments that hinder questionnaire completion, consciousness disorders * sensory impairments (e.g., severe visual or auditory deficits) that limit interaction with virtual reality.

Keywords: virtual reality relaxation cardiac rehabilitation kinesiophobia stress depression new technologies heart disease
sirolimus (rapamune®) for autosomal dominant polycystic kidney disease (adpkd)

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Summary: the aim of our study is to investigate whether rapamune used at a low dose (2 mg/d) retards cyst growth and slows renal functional deterioration in patients with adpkd.

currently there is no treatment for adpkd other than supportive care and blood pressure control. usually dialytic treatment or renal transplantation becomes necessary when the disease has progressed to end-stage renal failure.we and others could demonstrate that rapamycin, a classical mtor inhibitor, retards cyst growth and preserves renal function in a rodent model of adpkd. the aim of our study is to investigate whether rapamune (2 mg/d) retards cyst growth and slows renal functional deterioration in patients with adpkd. we anticipate that we can slow disease progression and delay the need for chronic renal replacement therapy by the inhibition of mtor with rapamune. this is a 24-month prospective, controlled, open label study with 2 parallel groups in patients with adpkd. patients will be randomized at a 1:1 ratio to one of the 2 treatment arms. primary endpoint is percentage change of renal volume measured by high resolution magnetic resolution imaging.

Eligibility criteria:
inclusion criteria: * male or female adpkd patient between 18 and 40 years of age * measured gfr higher than 70 ml/min 1.73m2 * documented kidney volume progression * informed consent exclusion criteria: * female of childbearing potential who is planning to become pregnant, who is pregnant and/or lactating, who is unwilling to use effective means of contraception * increased liver enzymes (2-fold above normal values) * hypercholesterolemia (fasting cholesterol \> 8 mmol/l) or hypertriglyceridaemia (\> 5 mmol/l) not controlled by lipid lowering therapy * granulocytopenia (white blood cell \< 3,000/mm3) or thrombocytopenia (platelets \< 100,000/mm3), * infection with hepatitis b or c, hiv * any past or present malignancy * mental illness that interfere with the patient ability to comply with the protocol * drug or alcohol abuse within one year of baseline * co-medication with strong inhibitor of cyp3a4 and or p-gp like voriconazole, ketoconazole, diltiazem, verapamil, erythromycin * co-medication with strong cyp3a4 and or p-gp inductor like rifampicin * known hypersensitivity to macrolides or rapamune

Keywords: adpkd autosomal dominant polycystic kidney disease sirolimus volumetry
feasibility of a video-oculography in patients with huntington's disease vog-hd study

Conditions: Huntington Disease

Summary: the purpose of this study is to know the limits of feasibility of a reliable oculomotor record for patient with huntington's disease.


Eligibility criteria:
inclusion criteria: * corrected visual acuity \>1/10 * aged over 18 years * patient with the mutation that is to say the presence of an abnormal number of trinuclide: cag\> 38 in the first exon of the huntingtin gene. * total functional capacity scale (cft) ≥ 3 exclusion criteria: * patients or trustworthy person who have not given their written consent, informed and signed. * patients are not affiliated or who are not entitled to social security * private patients of liberty by administrative or judicial decision, or patients supervision * associated disease with neurological repercussions

Keywords: video oculography
sustained effort network for treatment of status epilepticus/european academy of neurology registry on refractory status epilepticus (sense-ii/arouse)

Conditions: Status Epilepticus

Summary: sense-ii/arouse is a prospective, multicenter registry for patients treated for se. the primary objective is to document patients and se characteristics, treatment modalities, eeg features, and outcome of consecutive adults admitted fir se treatment in each of the participating centers and to identify predictors of outcome and refractoriness.

sense-ii/arouse is a prospective, multicenter, non-randomized, observational registry study of consecutive cases of se. we aimed to include university hospitals as well as non-university hospitals to enhance generalizability of the findings. currently, 13 high-volume medical centers in belgium, austria, germany, united kingdom, switzerland, no common management protocol will be imposed on the participating centers. however, most institutions have established a local protocol that is closely related to the most recent guidelines for the management of se published by the american epilepsy society (aes) in 2016. we will exclude patients with anoxic status epilepticus after cardiac arrest and patients younger than 18 years. clinical and eeg data will be collected prospectively from the admission of the patient to the discharge. data collection will be performed using research electronic data capture (redcap) electronic data capture tools hosted at erasme hospital in brussels, belgium. to reach sufficient statistical power for multivariate analysis, a cohort size of 3000 patients is targeted. the main objective of the study is to document patient characteristics, treatment modalities, eeg features and outcome of adults treated for se and identify predictors of outcome. the data collected in this study could also identify gaps and opportunities for the management of this medical emergency. lacking adequate prospective controlled trials, this will help both decision-making in clinical practice and designing future clinical trials. moreover, eeg data will help for a better electroencephalographic definition of se, possible se, and some boundary conditions, such as ictal-interictal continuum.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or above * patients admitted for management of status epilepticus as their primary diagnosis * patients admitted for another primary diagnosis but identified with status epilepticus during their acute hospital stay exclusion criteria: - patients with post-cardiac arrest se
effect of shock waves on dental parameters

Conditions: Tooth Stability; Blood Flow

Summary: this randomized clinical trial investigates the effect of the extracorporeal shockwave therapy (eswt) on periodontal and endodontical parameters. the eswt is a scientifically approved non invasive method to influence bone turnover and tissue regeneration. the hypotheses of this trial are that eswt increases the periodontal stability of orthodontically aligned teeth as well as increase the blood flow. increasing the periodontal stability would reduce the retention phase, relapse risk and accelerate the rehabilitation of the surrounding tissues.


Eligibility criteria:
inclusion criteria: * healthy patients which don´t fulfill the exclusion criteria exclusion criteria: * diseases (syndroms, infections,...) which influence the bone turnover and blood flow * medication, which influences the bone turnover and blood flow * pregnancy

Keywords: tooth mobility periodontal status irregularity index pulpal blood flow
use of stem cells in diabetes mellitus type 1

Conditions: Diabetes Mellitus Type 1

Summary: allogenic adipose derived mesenchymal stem cells will be injected into patients newly diagnosed with type 1 diabetes mellitus

adipose derived mesenchymal stem cells (ascs) are to be collected from blood group o donor, cells will be passaged to passage 5. before release the sample will be subject to our release criteria which include: testing for any bacterial or fungal growth as well as endotoxin and mycoplasma. all these tests must be negative. in addition the cell count and viability (must be more than 80%) are done before release. surface markers documentation is done on the cells before release using flow cytometry. the cells should be infused within 2 hours of release. the dose to is to be repeated after 6 months of a total of two doses in patients. tests and follow up are to be one at week 12, 24 and 36 when the study is stopped. these cells will be injected intravenously into patients newly diagnosed with type 1 diabetes mellitus.

Eligibility criteria:
inclusion criteria: 1. adult patients with type 1 diabetes mellitus. 2. age from 18 years to 35 years either gender. 3. duration of disease: not exceeding 3 years unless c-peptide is not less than 0.5 ng/ml 4. c-peptide at inclusion base line should not be less than 0.5 ng/ml 5. no clinical evidence of renal, retinal, vascular or skin complications 6. body mass index not exceeding 30 7. any hba1c 8. at least one positive antibody either anti-glutamic acid decarboxylase-65 or insulinoma-associated-2 autoantibodies (anti-1a2) 9. informed consent by patient exclusion criteria: 1. age less than 18 years and more than 35 years 2. pregnancy 3. married women or women expected to be married within the study period 4. history of allergy, cancer, bronchial asthma, liver disease or hepatitis 5. diabetic coma or pre-coma current or recent within the last 2 months 6. c-peptide less than 0.5 ng/ml 7. disease duration more than 3 yrs. 8. complication mentioned in 5 above in inclusion 9. non-consenting patient or withdrawal of consent. 10. bleeding disorders

Keywords: diabetes mellitus type 1 adipose derived mesenchymal stem cells
a study of the pharmacokinetics and pharmacodynamics of mk1809 (1809-001)(completed)

Conditions: Hypertension

Summary: the goal of this study is to identify at least one safe and well tolerated dose of mk1809 that has similar pharmacokinetic qualities as 100 mg losartan.


Eligibility criteria:
inclusion criteria: part 1: * nonsmoker for at least 6 months * body mass index (bmi) less than or equal to 29 kg/m2 * in overall good health part 2: * body mass index (bmi) greater than 18kg/m2 and less than or equal to 35kg/m2 * in overall good health (patients with hypertension and/or hyperlipidemia are accepted) exclusion criteria: part 1: * history of any cardiovascular disease or any clinically significant family history of cardiac arrhythmias or conduction abnormalities at an age less than 60 years * history of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder * history of cancer * clinically significant history of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines) * active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety) * history of asthma, severe wheezing, copd, or other pulmonary disease * individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties * major surgery, donated blood or participated in another investigational drug(s) trial within 30 days * illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years) * nitrate therapy within 4 weeks * history of significant drug allergy or history of food allergies part 2 * history of any clinically significant cardiac or cardiovascular disease (other than hypertension) * history of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder * history of cancer * history of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines) * active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety) * history of asthma, severe wheezing, copd, or other pulmonary disease * individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties * illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years) * surgery, significant blood loss, donated blood, or participated in another investigational drug(s) trial within 30 days * nitrate therapy within 4 weeks * history of significant drug allergy

Keywords: hypertension
effects of conventional physical therapy with and without scapular stabilization exercises in adhesive capsulitis.

Conditions: Adhesive Capsulitis

Summary: the objective of this study will be to determine the effects of conventional physical therapy with and without scapular stabilization exercises on pain, function, scapular dyskinesia, and proprioception in patients with adhesive capsulitis.

adhesive capsulitis is characterized by the gradual onset of severe shoulder pain with the progressive limitation of active and passive glenohumeral range of motion. due to capsular tightness and pain, scapular positioning and proprioception get affected. an increase in the abnormal positioning of the scapula and proprioception deficit disturbs the whole biomechanics of the shoulder joint and are the main causes of residual pain and stiffness following pt treatment. in previous studies, several studies have reported the effects of scapular stabilization exercises on pain, rom, and function but there is a paucity of literature available on specifically addressing scapular dyskinesis and joint position sense in patients with adhesive capsulitis. scapular stabilization techniques will help to improve proprioception and the length-tension relationship of the scapular muscles, which may effectively reduce the time taken for the rehabilitation of the patient with adhesive capsulitis of the shoulder joint.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic adhesive capsulitis for more than 4 months (stage 2) * unilateral idiopathic adhesive capsulitis * shoulder pain on nprs ≥5 * restricted rom (loss of ≥ 25% relative to non-involved shoulder in one or multidirectional) * patients volunteered to participate in the study and signed informed consent. exclusion criteria: * history of shoulder surgery or manipulation under anesthesia * unstable fractures, rheumatoid arthritis and those with severe joint pain unrelieved by rest * neurologic deficits affecting shoulder functioning during daily activities * pain or disorders of the cervical spine, elbow, wrist, or hand * other pathological conditions involving the shoulder (rotator cuff tear, tendinitis, etc.)

Keywords: adhesive capsulitis scapular dyskinesis proprioception scapular stabilization exercises